- Home
- IMMX vs PDSB Comparison
IMMX vs PDSB Comparison
Compare IMMX & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- PDSB
- Stock Information
- Founded
- IMMX 2014
- PDSB 2005
- Country
- IMMX United States
- PDSB United States
- Employees
- IMMX N/A
- PDSB N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- PDSB Health Care
- Exchange
- IMMX Nasdaq
- PDSB Nasdaq
- Market Cap
- IMMX 61.1M
- PDSB 72.2M
- IPO Year
- IMMX 2021
- PDSB N/A
- Fundamental
- Price
- IMMX $2.65
- PDSB $1.24
- Analyst Decision
- IMMX Strong Buy
- PDSB Strong Buy
- Analyst Count
- IMMX 1
- PDSB 2
- Target Price
- IMMX $7.00
- PDSB $10.00
- AVG Volume (30 Days)
- IMMX 137.1K
- PDSB 473.1K
- Earning Date
- IMMX 08-11-2025
- PDSB 08-12-2025
- Dividend Yield
- IMMX N/A
- PDSB N/A
- EPS Growth
- IMMX N/A
- PDSB N/A
- EPS
- IMMX N/A
- PDSB N/A
- Revenue
- IMMX N/A
- PDSB N/A
- Revenue This Year
- IMMX N/A
- PDSB N/A
- Revenue Next Year
- IMMX N/A
- PDSB N/A
- P/E Ratio
- IMMX N/A
- PDSB N/A
- Revenue Growth
- IMMX N/A
- PDSB N/A
- 52 Week Low
- IMMX $1.26
- PDSB $0.85
- 52 Week High
- IMMX $3.00
- PDSB $4.42
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- PDSB 39.29
- Support Level
- IMMX $2.16
- PDSB $1.20
- Resistance Level
- IMMX $2.80
- PDSB $1.40
- Average True Range (ATR)
- IMMX 0.17
- PDSB 0.10
- MACD
- IMMX 0.04
- PDSB -0.03
- Stochastic Oscillator
- IMMX 80.00
- PDSB 12.50
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.